Efficacies of Cognitive Interventions in the Elderly with Subjective Cognitive Decline: A Prospective, Three-Arm, Controlled Trial.
Alzheimer's disease
cognitive benefit
cognitive intervention
cognitive resilience
lifestyle modification
subjective cognitive decline
Journal
Journal of clinical neurology (Seoul, Korea)
ISSN: 1738-6586
Titre abrégé: J Clin Neurol
Pays: Korea (South)
ID NLM: 101252374
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
07
08
2019
revised:
02
02
2020
accepted:
07
02
2020
entrez:
23
4
2020
pubmed:
23
4
2020
medline:
23
4
2020
Statut:
ppublish
Résumé
A cognitive intervention (CI) is thought to improve cognition and delay cognitive decline via neuronal plasticity and cognitive resilience. Subjective cognitive decline (SCD) might be the first symptomatic stage of Alzheimer's disease, but few studies have examined the beneficial effect of CIs in SCD. We aimed to determine the efficacy of a 12-week, small-group-based, multidomain CI in elderly patients with SCD. Participants diagnosed with SCD (aged 55-75 years) were consecutively allocated to three groups: group 1, which received group-based CI implementation with lifestyle modifications; group 2, which received home-based lifestyle modifications without CI; and group 3, in which no action was taken. The primary outcome variables were the scores on computerized tests of the Cambridge Neuropsychological Test Automated Battery (CANTAB). The secondary outcomes included scores on tests evaluating general cognition, memory, visuospatial, and executive functions, as well as scores for the quality of life (QoL), anxiety, depression, and degree of subjective complaints. Changes in scores during the study period were compared between groups. The study was completed by 56 SCD participants. The baseline characteristics did not differ among the groups. The primary outcomes (CANTAB scores) did not differ among the groups. However, the outcomes for phonemic word fluency, verbal memory, QoL, and mood were better for group 1 than for the other two groups. Improvements in verbal memory function and executive function were related to the baseline cognitive scores and group differences. CI in SCD seems to be partially beneficial for executive function, memory, QoL, and mood, suggesting that CI is a useful nonpharmacological treatment option in this population.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
A cognitive intervention (CI) is thought to improve cognition and delay cognitive decline via neuronal plasticity and cognitive resilience. Subjective cognitive decline (SCD) might be the first symptomatic stage of Alzheimer's disease, but few studies have examined the beneficial effect of CIs in SCD. We aimed to determine the efficacy of a 12-week, small-group-based, multidomain CI in elderly patients with SCD.
METHODS
METHODS
Participants diagnosed with SCD (aged 55-75 years) were consecutively allocated to three groups: group 1, which received group-based CI implementation with lifestyle modifications; group 2, which received home-based lifestyle modifications without CI; and group 3, in which no action was taken. The primary outcome variables were the scores on computerized tests of the Cambridge Neuropsychological Test Automated Battery (CANTAB). The secondary outcomes included scores on tests evaluating general cognition, memory, visuospatial, and executive functions, as well as scores for the quality of life (QoL), anxiety, depression, and degree of subjective complaints. Changes in scores during the study period were compared between groups.
RESULTS
RESULTS
The study was completed by 56 SCD participants. The baseline characteristics did not differ among the groups. The primary outcomes (CANTAB scores) did not differ among the groups. However, the outcomes for phonemic word fluency, verbal memory, QoL, and mood were better for group 1 than for the other two groups. Improvements in verbal memory function and executive function were related to the baseline cognitive scores and group differences.
CONCLUSIONS
CONCLUSIONS
CI in SCD seems to be partially beneficial for executive function, memory, QoL, and mood, suggesting that CI is a useful nonpharmacological treatment option in this population.
Identifiants
pubmed: 32319248
pii: 16.304
doi: 10.3988/jcn.2020.16.2.304
pmc: PMC7174106
doi:
Types de publication
Journal Article
Langues
eng
Pagination
304-313Subventions
Organisme : Asan Institute for Life Sciences, Asan Medical Center
ID : 2011-0104
Pays : Korea
Organisme : Korea Health Industry Development Institute
ID : HI18C2383
Pays : Republic of Korea
Informations de copyright
Copyright © 2020 Korean Neurological Association.
Déclaration de conflit d'intérêts
The authors have no potential conflicts of interest to disclose.
Références
Patient Educ Couns. 2005 Apr;57(1):106-14
pubmed: 15797159
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
Lancet. 2015 Jun 6;385(9984):2255-63
pubmed: 25771249
Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S98-S108
pubmed: 18632010
Curr Psychiatry Rep. 2010 Feb;12(1):20-7
pubmed: 20425306
Patient Educ Couns. 2007 Feb;65(2):205-13
pubmed: 16956743
J Psychosom Res. 2002 Feb;52(2):69-77
pubmed: 11832252
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Alzheimers Dement. 2018 Mar;14(3):263-270
pubmed: 29055814
J Int Neuropsychol Soc. 2002 Mar;8(3):448-60
pubmed: 11939702
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Aging Ment Health. 2012;16(2):135-44
pubmed: 21780962
J Gerontol A Biol Sci Med Sci. 2004 Sep;59(9):M940-57
pubmed: 15472160
Psychosom Med. 2002 May-Jun;64(3):510-9
pubmed: 12021425
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
Am J Geriatr Psychiatry. 2009 Mar;17(3):179-87
pubmed: 19225276
Arch Gerontol Geriatr. 2008 Nov-Dec;47(3):302-10
pubmed: 17936377
Br J Clin Psychol. 1982 Feb;21(1):1-16
pubmed: 7126941
Int J Geriatr Psychiatry. 2013 Feb;28(2):208-15
pubmed: 22528470
Neurosci Biobehav Rev. 2012 Apr;36(4):1163-78
pubmed: 22322184
BMC Med. 2012 Mar 27;10:30
pubmed: 22453114
Trends Cogn Sci. 2013 Oct;17(10):502-9
pubmed: 24018144
J Mol Neurosci. 2016 Nov;60(3):354-361
pubmed: 27514526
Am J Geriatr Psychiatry. 2006 Jun;14(6):538-45
pubmed: 16731723
Front Aging Neurosci. 2010 Nov 29;2:150
pubmed: 21151819
PLoS One. 2012;7(1):e29676
pubmed: 22253758
J Alzheimers Dis. 2014;42 Suppl 4:S551-9
pubmed: 25171716
Int J Geriatr Psychiatry. 2008 Nov;23(11):1172-4
pubmed: 18496884
Neuropsychol Rev. 2017 Sep;27(3):245-257
pubmed: 28271346
PLoS One. 2015 Apr 21;10(4):e0123251
pubmed: 25898367
J Alzheimers Dis. 2014;41(3):779-91
pubmed: 24685630
JAMA. 2002 Nov 13;288(18):2271-81
pubmed: 12425704
Am J Alzheimers Dis Other Demen. 2013 Sep;28(6):560-7
pubmed: 23823142
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Curr Alzheimer Res. 2015;12(6):527-42
pubmed: 26027815